DK0417725T3 - Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler. - Google Patents

Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler.

Info

Publication number: DK0417725T3
Authority: DK; Denmark
Prior art keywords: bile acid; substance; acid residue; acid derivatives; absorbed
Prior art date: 1989-09-14

Application number

DK90117470.6T

Other languages

English (en)

Inventor

Werner Dr Kramer

G Wess

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-14

Filing date

1990-09-11

Publication date

1997-11-03

1990-09-11 Application filed by Hoechst Ag filed Critical Hoechst Ag

1997-11-03 Application granted granted Critical

1997-11-03 Publication of DK0417725T3 publication Critical patent/DK0417725T3/da

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 5
239000003814 drug Substances 0.000 title abstract 3
239000013543 active substance Substances 0.000 abstract 3
210000004185 liver Anatomy 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
206010016654 Fibrosis Diseases 0.000 abstract 1
230000009102 absorption Effects 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
125000003158 alcohol group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000003443 antiviral agent Substances 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
230000036772 blood pressure Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000007882 cirrhosis Effects 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000010235 enterohepatic circulation Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000009103 reabsorption Effects 0.000 abstract 1
239000002461 renin inhibitor Substances 0.000 abstract 1
229940086526 renin-inhibitors Drugs 0.000 abstract 1
150000003839 salts Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Diabetes (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Lubricants (AREA)
Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
Control Of Heat Treatment Processes (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

DK90117470.6T 1989-09-14 1990-09-11 Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler. DK0417725T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3930696A DE3930696A1 (de)	1989-09-14	1989-09-14	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
DK0417725T3 true DK0417725T3 (da)	1997-11-03

Family

ID=6389405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90117470.6T DK0417725T3 (da)	1989-09-14	1990-09-11	Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler.

Country Status (21)

Country	Link
US (3)	US5462933A (da)
EP (1)	EP0417725B1 (da)
JP (3)	JP2568306B2 (da)
KR (1)	KR0166962B1 (da)
AT (1)	ATE152117T1 (da)
AU (1)	AU637822B2 (da)
CA (1)	CA2025294C (da)
CY (1)	CY2112B1 (da)
DE (2)	DE3930696A1 (da)
DK (1)	DK0417725T3 (da)
ES (1)	ES2100858T3 (da)
FI (1)	FI105155B (da)
GR (1)	GR3024095T3 (da)
HU (1)	HU213395B (da)
IE (1)	IE903329A1 (da)
IL (1)	IL95668A (da)
NO (1)	NO303450B1 (da)
NZ (1)	NZ235285A (da)
PT (1)	PT95299B (da)
TW (1)	TW199097B (da)
ZA (1)	ZA907300B (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
JP2611073B2 (ja) *	1990-07-26	1997-05-21	モンサントカンパニー	新規ポリアミンの製造方法
US5795870A (en) *	1991-12-13	1998-08-18	Trustees Of Princeton University	Compositions and methods for cell transformation
US5693769A (en) *	1991-12-13	1997-12-02	Transcell Technologies, Inc.	Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
AU653658B2 (en) *	1991-12-20	1994-10-06	Hoechst Aktiengesellschaft	Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
EP0548793A3 (en) *	1991-12-20	1995-11-02	Hoechst Ag	Ethylenic-unsaturated bile acid derivatives, process for their production and preliminary processes therefor
US5639866A (en) *	1993-02-23	1997-06-17	Princeton University	Single-step formation of multiple glycosidic linkages
IL108748A0 (en) *	1993-02-23	1994-08-26	Univ Princeton	Solution and solid-phase formation of glycosidic linkages
TW289757B (da) *	1993-05-08	1996-11-01	Hoechst Ag
TW289021B (da) *	1993-05-08	1996-10-21	Hoechst Ag
TW289020B (da) *	1993-05-08	1996-10-21	Hoechst Sktiengesellschaft
IT1269839B (it) *	1994-05-26	1997-04-15	Bracco Spa	Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5585470A (en) *	1994-06-23	1996-12-17	Transcell Technologies, Inc.	Process for the manufacture of 3-amino-substituted glycosylated bile acids
US6143864A (en) *	1994-06-28	2000-11-07	Merck & Co., Inc.	Peptides
US6107494A (en) *	1994-09-13	2000-08-22	G.D. Searle And Company	Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en)	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE4432708A1 (de)	1994-09-14	1996-03-21	Hoechst Ag	Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
IL142650A (en) *	1998-04-08	2007-06-03	Galmed Int Ltd	Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
IL123998A (en) *	1998-04-08	2004-09-27	Galmed Int Ltd	Conjugates of bile salts and pharmaceutical preparations containing them
IL139241A0 (en) *	1998-05-13	2001-11-25	Novo Nordisk As	Meiosis regulating compounds
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
PT1140190E (pt)	1998-12-23	2003-02-28	Searle Llc	Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
IT1304501B1 (it) *	1998-12-23	2001-03-19	Bracco Spa	Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
EP1140186B1 (en)	1998-12-23	2003-06-04	G.D. Searle LLC.	Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
EP1342475A1 (en)	1998-12-23	2003-09-10	G.D. Searle LLC.	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DK1140185T3 (da)	1998-12-23	2003-09-29	Searle Llc	Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
DK1140184T3 (da)	1998-12-23	2003-09-29	Searle Llc	Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
MXPA01006472A (es)	1998-12-23	2004-03-10	Searle Llc	Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
GB9907048D0 (en) *	1999-03-27	1999-05-19	Karobio Ab	Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
GB2355009A (en) *	1999-07-30	2001-04-11	Univ Glasgow	Peptides conjugated to bile acids/salts
WO2001020331A1 (en)	1999-09-14	2001-03-22	Xenoport, Inc.	Substrates and screening methods for transport proteins
DE19950686B4 (de) *	1999-10-21	2006-06-29	Martin-Luther-Universität Halle-Wittenberg	Multifunktionelle Spacer
EP1286984A2 (en)	2000-03-10	2003-03-05	Pharmacia Corporation	Method for the preparation of tetrahydrobenzothiepines
EP1361847A2 (en) *	2000-10-06	2003-11-19	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) *	2000-10-06	2002-04-15	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002243204A1 (en)	2000-10-06	2002-06-11	Xenoport, Inc.	Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US8975246B2 (en)	2001-04-17	2015-03-10	Galmed Research And Development Ltd.	Bile acid or bile salt fatty acid conjugates
US7053076B2 (en) *	2001-08-29	2006-05-30	Xenoport, Inc.	Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6740663B2 (en)	2001-11-02	2004-05-25	G.D. Searle, Llc	Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
AU2003207431A1 (en)	2002-01-17	2003-09-02	Pharmacia Corporation	Novel alkyl/aryl hydroxy or keto thiepines.
CN100348609C (zh) *	2002-06-19	2007-11-14	卡罗生物股份公司	治疗代谢紊乱的糖皮质激素受体配基
US7141559B2 (en)	2002-06-19	2006-11-28	Karo Bio Ab	Glucocorticoid receptor ligands for the treatment of metabolic disorders
AU2003293423A1 (en)	2002-12-06	2004-06-30	Xenoport, Inc.	Carbidopa prodrugs and uses thereof
CA2512310C (en) *	2003-01-13	2012-09-25	Bracco Imaging S.P.A.	Improved linkers for radiopharmaceutical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
US7205415B2 (en) *	2004-01-02	2007-04-17	Hetero Drugs, Ltd.	Process for the preparation of simvastatin
ATE442865T1 (de) *	2004-04-08	2009-10-15	Jado Technologies Gmbh	Dreigeteilte konjugate mit einer struktur, die mit zellmembran-rafts interagieren und ihre verwendung
JP4896870B2 (ja) *	2004-04-08	2012-03-14	ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
WO2005113008A1 (en) *	2004-05-21	2005-12-01	Mediplex Corp.	Delivery agents for enhancing mucosal absorption of therapeutic agents
US7323585B2 (en) *	2004-06-04	2008-01-29	Xenoport, Inc.	Levodopa prodrugs, and compositions and uses thereof
WO2005118612A1 (en) *	2004-06-04	2005-12-15	Sonus Pharmaceuticals, Inc.	Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
US7342131B2 (en) *	2004-06-04	2008-03-11	Xenoport, Inc.	Levodopa prodrugs, and compositions and uses thereof
EP1959948B1 (en) *	2005-12-05	2012-07-18	XenoPort, Inc.	Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7829592B2 (en) *	2006-12-21	2010-11-09	Xenoport, Inc.	Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) *	2006-12-21	2008-11-16	Xenoport Inc	Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
CN101367859B (zh) *	2007-08-17	2011-05-11	中国人民解放军军事医学科学院毒物药物研究所	脂肪酸胆汁酸偶合物及其医药用途
KR101239008B1 (ko) *	2008-03-31	2013-03-04	한양대학교 산학협력단	바일산 유도체 및 그의 응용
AU2009279090A1 (en) *	2008-08-06	2010-02-11	Novo Nordisk Health Care Ag	Conjugated proteins with prolonged in vivo efficacy
WO2010047775A2 (en) *	2008-10-20	2010-04-29	Xenoport, Inc.	Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) *	2008-10-20	2013-03-19	Xenoport, Inc.	Levodopa prodrug mesylate hydrate
CA2747825A1 (en)	2009-01-22	2010-07-29	Novo Nordisk Health Care Ag	Stable growth hormone compounds
EP2461831B1 (en)	2009-08-06	2018-11-21	Novo Nordisk Health Care AG	Growth hormones with prolonged in-vivo efficacy
WO2011056240A2 (en)	2009-11-09	2011-05-12	Xenoport, Inc.	Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
RU2012134974A (ru)	2010-01-22	2014-02-27	Ново Нордиск Хелс Кеа Аг	Стабилизированное соединение гормона роста
RU2605627C2 (ru)	2010-01-22	2016-12-27	Ново Нордиск Хелс Кеа Аг	Гормоны роста с пролонгированной эффективностью in vivo
EP3593802A3 (en)	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
KR20160003664A (ko)	2013-03-15	2016-01-11	루메나 파마수티컬즈, 인코포레이티드	바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
EP2968230A2 (en)	2013-03-15	2016-01-20	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
EP2981282B1 (en)	2013-04-05	2020-11-04	Novo Nordisk Health Care AG	Growth hormone compound formulation
CN104693264B (zh) *	2015-02-09	2016-09-21	华南理工大学	一种化合物及其制备方法和应用
CN106046101B (zh) *	2016-05-25	2018-01-05	华南理工大学	一种糖原磷酸化酶抑制剂及其制备方法和应用
WO2017210147A1 (en)	2016-05-29	2017-12-07	Wei Jia	Liver disease-related biomarkers and methods of use thereof
CN106496300B (zh) *	2016-10-19	2018-05-18	上海博志研新药物技术有限公司	花生胆酸及其中间体的制备方法
CA3129826A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Methods for treating cholestasis
CN116925168A (zh) *	2019-08-23	2023-10-24	深圳云合医药科技合伙企业(有限合伙)	胆汁酸衍生物及其组合物和应用
WO2023105494A1 (en)	2021-12-10	2023-06-15	Universidade Do Porto	Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2441129A (en) *	1942-05-23	1948-05-11	Berczeller Arpad	Bile acid derivatives of aryl sulfonamides
US3937815A (en) *	1975-12-05	1976-02-10	SPA--Societa Prodotti Antibiotici S.p.A.	Lysozyme derivatives
FR2457302A1 (fr) *	1979-05-23	1980-12-19	Roussel Uclaf	Nouveau procede de purification de l'acide ursodesoxycholique
JPS5754151A (en) *	1980-09-18	1982-03-31	Takeda Chem Ind Ltd	Physiologically active substance b-52653 and its preparation
JPS57131735A (en) *	1981-02-09	1982-08-14	Takeda Chem Ind Ltd	Preparation of quinones
US4418059A (en) *	1981-07-20	1983-11-29	Montefiore Medical Center	Nucleoside ester compositions
US4499020A (en) *	1981-07-21	1985-02-12	Montefiore Hospital And Medical Center, Inc.	Mixed anhydrides and processes thereof
FR2511007A1 (fr) *	1981-08-07	1983-02-11	Roussel Uclaf	Procede de preparation de l'acide ursodesoxycholique a partir de l'acide 3a, 7b, 12a-trihydroxycholanique et produit intermediaire utilises
NL8201492A (nl) *	1982-04-07	1983-11-01	Rijksuniversiteit	Werkwijze ter bereiding van een op de 4-plaats equatoriaal gesubstitueerde symmetrisch-polycycloethyleenverbinding; op de 4-plaats equatoriaal gesubstitueerde symmetrisch-polycycloethyleenverbinding alsmede een op basis van de verbinding bereid thermochemiluminescerend merkmateriaal of thermochemiluminescerend sondeermateriaal.
EP0105404A1 (en) *	1982-09-30	1984-04-18	Merck & Co. Inc.	Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation
DE3432094A1 (de) *	1984-08-31	1986-03-06	Hoechst Ag, 6230 Frankfurt	Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
JPS62175497A (ja) *	1986-01-28	1987-08-01	Wakunaga Pharmaceut Co Ltd	胆汁酸誘導体およびその製造法
US5238948A (en) *	1987-02-10	1993-08-24	Hoechst Aktiengesellschaft	Pyridine-2,4- and -2,5-dicarboxylic acid derivatives and medicaments based on these compounds
EP0307342B1 (de) *	1987-07-10	1996-01-03	Hoechst Aktiengesellschaft	3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
US4968790A (en) *	1988-08-12	1990-11-06	American Cyanamid Company	Antidiabetic phosphates
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DE3931432A1 (de) *	1989-09-21	1991-04-04	Hoechst Ag	Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen

1989
- 1989-09-14 DE DE3930696A patent/DE3930696A1/de not_active Withdrawn
1990
- 1990-09-11 DK DK90117470.6T patent/DK0417725T3/da active
- 1990-09-11 ES ES90117470T patent/ES2100858T3/es not_active Expired - Lifetime
- 1990-09-11 AT AT90117470T patent/ATE152117T1/de not_active IP Right Cessation
- 1990-09-11 DE DE59010706T patent/DE59010706D1/de not_active Expired - Lifetime
- 1990-09-11 EP EP90117470A patent/EP0417725B1/de not_active Expired - Lifetime
- 1990-09-12 FI FI904497A patent/FI105155B/fi active IP Right Grant
- 1990-09-12 IL IL9566890A patent/IL95668A/en unknown
- 1990-09-12 NZ NZ235285A patent/NZ235285A/xx unknown
- 1990-09-13 IE IE332990A patent/IE903329A1/en not_active IP Right Cessation
- 1990-09-13 ZA ZA907300A patent/ZA907300B/xx unknown
- 1990-09-13 JP JP2241338A patent/JP2568306B2/ja not_active Expired - Lifetime
- 1990-09-13 AU AU62441/90A patent/AU637822B2/en not_active Expired
- 1990-09-13 NO NO903999A patent/NO303450B1/no not_active IP Right Cessation
- 1990-09-13 HU HU905893A patent/HU213395B/hu unknown
- 1990-09-13 PT PT95299A patent/PT95299B/pt not_active IP Right Cessation
- 1990-09-13 CA CA002025294A patent/CA2025294C/en not_active Expired - Lifetime
- 1990-09-14 TW TW079107732A patent/TW199097B/zh active
- 1990-09-14 KR KR1019900014542A patent/KR0166962B1/ko not_active Expired - Lifetime
1994
- 1994-03-10 US US08/208,192 patent/US5462933A/en not_active Expired - Lifetime
1995
- 1995-06-07 US US08/476,941 patent/US5646272A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,689 patent/US5668126A/en not_active Expired - Lifetime
- 1995-09-07 JP JP7254511A patent/JP2642089B2/ja not_active Expired - Lifetime
- 1995-09-07 JP JP7254512A patent/JP2642090B2/ja not_active Expired - Lifetime
1997
- 1997-07-15 GR GR970401746T patent/GR3024095T3/el unknown
1998
- 1998-09-29 CY CY9800029A patent/CY2112B1/xx unknown

Also Published As

Publication number	Publication date
IL95668A0 (en)	1991-06-30
KR910006319A (ko)	1991-04-29
KR0166962B1 (ko)	1999-01-15
JPH03109396A (ja)	1991-05-09
JP2642090B2 (ja)	1997-08-20
ATE152117T1 (de)	1997-05-15
ZA907300B (en)	1991-06-26
PT95299B (pt)	1997-06-30
HU905893D0 (en)	1991-03-28
EP0417725A2 (de)	1991-03-20
IL95668A (en)	1995-03-30
JPH0892277A (ja)	1996-04-09
EP0417725B1 (de)	1997-04-23
JP2568306B2 (ja)	1997-01-08
US5646272A (en)	1997-07-08
FI904497A0 (fi)	1990-09-12
CY2112B1 (en)	2002-04-26
EP0417725A3 (en)	1992-03-18
HU213395B (en)	1997-06-30
HUT56115A (en)	1991-07-29
NO903999D0 (no)	1990-09-13
DE59010706D1 (de)	1997-05-28
TW199097B (da)	1993-02-01
US5668126A (en)	1997-09-16
CA2025294C (en)	2001-11-27
NZ235285A (en)	1993-05-26
CA2025294A1 (en)	1991-03-15
JPH0892276A (ja)	1996-04-09
US5462933A (en)	1995-10-31
ES2100858T3 (es)	1997-07-01
IE903329A1 (en)	1991-04-10
PT95299A (pt)	1991-05-22
AU637822B2 (en)	1993-06-10
AU6244190A (en)	1991-03-21
NO303450B1 (no)	1998-07-13
JP2642089B2 (ja)	1997-08-20
NO903999L (no)	1991-03-15
GR3024095T3 (en)	1997-10-31
FI105155B (fi)	2000-06-30
DE3930696A1 (de)	1991-03-28

Publication	Publication Date	Title
NO903999L (no)	1991-03-15	Fremgangsmaate for fremstilling av gallesyrederivater og deres anvendelse som legemidler.
DE3887618D1 (de)	1994-03-17	Polyschwefelsäureester von Bis-aldonsäureamiden und deren Derivaten, Verfahren zu ihrer Herstellung und Arzneimittel.
ATE255450T1 (de)	2003-12-15	Matrix für iontophorese
DK280884D0 (da)	1984-06-07	Galeniske praeparatformer for orale antidiabetica og fremgangsmaade til deres fremstilling
NO914792D0 (no)	1991-12-05	Gallesyrederivater, deres fremstilling og anvendelse som legemiddel
PT91108A (pt)	1990-02-08	Processo para a preparacao de uma composicao farmaceutica que compreende um ingrediente activo tal como um sal do acido colico e um produto inibidor para activar a absorcao do ingrediente activo pelo corpo humano
DE3679722D1 (de)	1991-07-18	Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung.
ATE10626T1 (de)	1984-12-15	N-substituierte omega-(2-oxo-imidazolin-1-yl)alkans[uren, deren salze und ester, verfahren zu deren herstellung und diese aktiven substanzen enthaltende pharmazeutische zubereitungen.
DE69005398D1 (de)	1994-02-03	Topisch kosmetisch anzuwendende depolymerisierte Nukleinsäuren enthaltende Arzneizubereitungen.
ATE59554T1 (de)	1991-01-15	Auf mercaptoethansulfonsaeuren basierende pharmazeutische zusammensetzungen, organische abkoemmlinge von mercaptoethansulfonsaeuren sowie verfahren zu deren herstellung.
ATE111525T1 (de)	1994-09-15	Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
ES2073418T3 (es)	1995-08-16	Nuevos nitratos organicos y procedimiento para su preparacion.
IE50550B1 (en)	1986-05-14	Pharmaceutical compositions of therapeutic value in the treatment of acute pulmonary edema,some shock conditions and hyperfibrinolysis
ATE89744T1 (de)	1993-06-15	Pharmazeutische zusammensetzung.
DE3884508D1 (de)	1993-11-04	Cystein-derivate mit expectorans-wirkung.
DE3579074D1 (de)	1990-09-13	Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
ES2072904T3 (es)	1995-08-01	Utilizacion de derivados de dextrina para el tratamiento de condiciones acidas.
CN1048157C (zh)	2000-01-12	核糖核酸与肝素复方注射剂
ATE52791T1 (de)	1990-06-15	In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
JPS56138115A (en)	1981-10-28	Suppository containing acidic amino acid or derivative thereof
KR890003403A (ko)	1989-04-14	당뇨병의 합병증을 예방하거나 치료하기 위한 제제
JPS5780314A (en)	1982-05-19	Pharmaceutical preparation to be medicated to rectum
Zakharevskiĭ et al.	1976	Biochemical mechanisms of the antihypoxic effect of amichlorphen (diethylaminoethylamide parachlorphenoxyacetic acid)
ATE53384T1 (de)	1990-06-15	3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.
JPS51123834A (en)	1976-10-28	A medicine against the headache